An update from BioCryst ( (BCRX) ) is now available.
On February 28, 2025, BioCryst Pharmaceuticals announced the resignation of its Chief Financial Officer, Anthony Doyle, effective April 9, 2025. Doyle, who has been with the company since April 2020, played a crucial role during the global launch of ORLADEYO and in strengthening the company’s financial position as it nears profitability. His departure is not due to any disagreements with the company, and he will remain in his role until April 9 to ensure a smooth transition. The company has initiated a search for a new CFO.
More about BioCryst
BioCryst Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of oral and small-molecule drugs. The company is known for its product ORLADEYO, which targets rare diseases.
YTD Price Performance: 9.96%
Average Trading Volume: 2,682,187
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.8B
For a thorough assessment of BCRX stock, go to TipRanks’ Stock Analysis page.